Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial expected mid-2023 Webcast to be held today, February 28, 2023 , at 8:30 am ET GAITHERSBURG, Md. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc.

GAITHERSBURG, Md. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.

Mr. Jordt brings over 25 years of industry experience in corporate strategy and business development GAITHERSBURG, Md. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business

GAITHERSBURG, Md. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison , Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research , will deliver an oral presentation of the